Eflornithine not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Antiprotozoal; Decarboxylase Inhibitor FDA class
- How it’s given
- “Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule”In the company’s words, NCT05879367 on ClinicalTrials.gov
- Tested for
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
- Main trialPhase 1
- “The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.”In the company’s words, NCT05879367 on ClinicalTrials.gov
Other drugs for Glioblastoma, IDH-wildtype
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2026 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026